A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Transgene
Novartis
Numab Therapeutics AG
NBE-Therapeutics AG
Nektar Therapeutics
Eli Lilly and Company
Tocagen Inc.